Kyverna Therapeutics (NASDAQ:KYTX) Downgraded to Sell Rating by Wall Street Zen

Kyverna Therapeutics (NASDAQ:KYTX) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

KYTX has been the topic of several other research reports. JPMorgan Chase & Co. decreased their target price on Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Friday, March 27th. Finally, HC Wainwright upped their target price on Kyverna Therapeutics from $20.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, May 15th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $30.00.

Kyverna Therapeutics Price Performance

Kyverna Therapeutics stock opened at $8.52 on Friday. Kyverna Therapeutics has a 12 month low of $2.47 and a 12 month high of $13.67. The stock’s 50 day moving average is $9.03 and its 200-day moving average is $8.50. The company has a current ratio of 8.15, a quick ratio of 8.15 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $517.93 million, a price-to-earnings ratio of -2.60 and a beta of 2.05.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its earnings results on Tuesday, May 12th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.09. Equities research analysts expect that Kyverna Therapeutics will post -2.81 EPS for the current year.

Institutional Investors Weigh In On Kyverna Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in KYTX. Bank of America Corp DE lifted its stake in Kyverna Therapeutics by 41.6% during the fourth quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock worth $81,000 after purchasing an additional 6,400 shares during the last quarter. Cubist Systematic Strategies LLC lifted its stake in Kyverna Therapeutics by 31.1% during the first quarter. Cubist Systematic Strategies LLC now owns 68,628 shares of the company’s stock worth $132,000 after purchasing an additional 16,267 shares during the last quarter. AQR Capital Management LLC bought a new stake in Kyverna Therapeutics during the first quarter worth $137,000. Rhumbline Advisers lifted its stake in Kyverna Therapeutics by 22.0% during the first quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock worth $61,000 after purchasing an additional 5,694 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in Kyverna Therapeutics during the second quarter worth $107,000. 18.08% of the stock is currently owned by institutional investors.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.